# Sputum from Individuals with Primary Ciliary Dyskinesia Drives M2-like Macrophage Polarization

**Authors:** Jenny Wåhlander, Tobias Schmidt, Christine R. Hansen, Robin Kahn, Lisa I. Påhlman

PMC · DOI: 10.1007/s00408-025-00868-6 · Lung · 2026-01-26

## TL;DR

Sputum from people with primary ciliary dyskinesia causes macrophages to adopt a pro-resolution, phagocytic M2-like state, which may influence lung disease progression.

## Contribution

This study reveals that PCD sputum drives M2-like macrophage polarization, offering new insights into the immune response in PCD-related bronchiectasis.

## Key findings

- PCD sputum increased macrophage phagocytosis and M2 surface markers like CD163 and CD206.
- PCD sputum reduced secretion of proinflammatory cytokines IL-6 and IL-1β.
- M1 markers CD40 and CD80 were downregulated in macrophages exposed to PCD sputum.

## Abstract

Primary ciliary dyskinesia (PCD) is a rare, congenital condition in which impaired ciliary function leads to bronchiectasis and progressive lung function decline. Bronchiectasis development is believed to involve infection and inflammation but is incompletely understood. Macrophages play a central role in cellular immune response, contributing to both pathogen clearance and immunoregulation. Depending on local stimuli, macrophages are polarized towards pro-inflammatory (M1) or pro-resolution/phagocytic (M2) phenotypes. This study aims to investigate the effects of PCD sputum on macrophage polarization.

Sputum from 27 individuals with PCD and seven healthy controls were used to stimulate healthy monocyte-derived macrophages. Macrophage polarization was determined by surface markers, phagocytic ability and cytokine production using flow cytometry and immunoassays.

Macrophages stimulated with PCD sputum exhibited enhanced phagocytosis (MFI 194268 vs. 58235, p = 0.0002), increased expression of M2-associated surface markers CD163, CD206 and CD16, and reduced secretion of proinflammatory cytokines IL-6 (10.38 vs. 113.22 pg/ml, p = 0.0013) and IL-1β (0.75 vs. 3.60 pg/ml, p < 0.0001). Concurrently, expressions of M1-associated surface markers CD40 and CD80 were reduced.

PCD sputum induced a phagocytosis prone, M2-like phenotype in healthy macrophages.

The online version contains supplementary material available at 10.1007/s00408-025-00868-6.

## Linked entities

- **Proteins:** CD163 (CD163 molecule), MRC1 (mannose receptor C-type 1), FCGR3B (Fc gamma receptor IIIb), CD40 (CD40 molecule), CD80 (CD80 molecule), IL6 (interleukin 6), IL1B (interleukin 1 beta)
- **Diseases:** Primary ciliary dyskinesia (MONDO:0016575), bronchiectasis (MONDO:0004822)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, MERTK (MER proto-oncogene, tyrosine kinase) [NCBI Gene 10461] {aka MER, RP38, Tyro12, c-Eyk, c-mer}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** juvenile idiopathic arthritis (MESH:D001171), lung function decline (MESH:D055370), chronic airway infection (MESH:D000088562), airway infections (MESH:D007239), dilation of the bronchi (MESH:D002311), sepsis (MESH:D018805), infectious (MESH:D003141), impaired ciliary function (MESH:D003072), COPD (MESH:D029424), airway dysfunction (MESH:D000402), Ciliary Dyskinesia (MESH:D002925), congenital disorder (MESH:D009358), congenital condition (MESH:D002908), cystic fibrosis (MESH:D003550), airway inflammation (MESH:D007249), necrosis (MESH:D009336), Bronchiectasis (MESH:D001987)
- **Chemicals:** Dexamethasone (MESH:D003907), cortisone (MESH:D003348), NHS (-), EDTA (MESH:D004492), Azithromycin (MESH:D017963), LPS (MESH:D008070), luminal (MESH:D010634), DTT (MESH:D004229), PBS (MESH:D007854)
- **Species:** Haemophilus influenzae (species) [taxon 727], Homo sapiens (human, species) [taxon 9606], Pseudomonas aeruginosa (species) [taxon 287]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12832589/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12832589/full.md

---
Source: https://tomesphere.com/paper/PMC12832589